Controversies surrounding percutaneous coronary intervention in the diabetic patient

References

• Polonsky KS. The past 200 years in diabetes. N Engl J Med. 2012;367(14):1332–1340. doi:10.1056/NEJMra1110560.
   PubMed Web of Science ®Google Scholar
• 2014 Statistics Report | Data & Statistics | Diabetes | CDC [Internet]. Available from: http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html.
   Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi:10.1016/j.diabres.2009.10.007.
   PubMed Web of Science ®Google Scholar
• Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Ser. J Am Coll Cardiol. 2014;64(17):1851–1856. doi:10.1016/j.jacc.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78. doi:10.1136/bmj.38678.389583.7C.
   PubMed Web of Science ®Google Scholar
• Wilson CS, Gau GT, Fulton RE, et al. Coronary artery disease in diabetic and nondiabetic patients: a clinical and angiographic comparison. Clin Cardiol. 1983;6(9):440–446. doi:10.1002/clc.v6:9.
   PubMed Web of Science ®Google Scholar
• De Waha S, Eitel I, Desch S, et al. Impact of multivessel coronary artery disease on reperfusion success in patients with ST-elevation myocardial infarction: a substudy of the AIDA STEMI trial. Eur Hear J Acute Cardiovasc Care. 2015 Dec 21. pii: 2048872615624240. [Epub ahead of print].
   Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234. doi:10.1056/NEJM199807233390404.
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–2581. doi:10.1001/jama.287.19.2570.
   PubMed Web of Science ®Google Scholar
• Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol. 2004;43(4):585–591. doi:10.1016/j.jacc.2003.08.050.
   PubMed Web of Science ®Google Scholar
• Ritsinger V, Saleh N, Lagerqvist B, et al. High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv. 2015;8(6):e002328. doi:10.1161/CIRCINTERVENTIONS.114.002328.
   Google Scholar
• Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294–2303. doi:10.1056/NEJMicm020037.
   PubMed Web of Science ®Google Scholar
• Vikramadithyan RK, Hu Y, Noh H-L, et al. Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest. 2005;115(9):2434–2443. doi:10.1172/JCI24819.
   PubMed Web of Science ®Google Scholar
• Tousoulis D, Papageorgiou N, Androulakis E, et al. Diabetes mellitus-associated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62(8):667–676. doi:10.1016/j.jacc.2013.03.089.
   PubMed Web of Science ®Google Scholar
• Selvin E, Coresh J, Golden SH, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005;165(16):1910–1916. doi:10.1001/archinte.165.16.1910.
   PubMedGoogle Scholar
• Conaway DG, O’Keefe JH, Reid KJ, et al. Frequency of undiagnosed diabetes mellitus in patients with acute coronary syndrome. Am J Cardiol. 2005;96(3):363–365. doi:10.1016/j.amjcard.2005.03.076.
   PubMed Web of Science ®Google Scholar
• Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013;165(6):918–925.e2. doi:10.1016/j.ahj.2013.01.005.
   PubMed Web of Science ®Google Scholar
• Arnold SV, Stolker JM, Lipska KJ, et al. Recognition of incident diabetes mellitus during an acute myocardial infarction. Circ Cardiovasc Qual Outcomes. 2015;8(3):260–267.
   PubMed Web of Science ®Google Scholar
• Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of pima Indians. N Engl J Med. 1993;329(27):1988–1992.
   PubMed Web of Science ®Google Scholar
• Selph S, Dana T, Blazina I, et al. Screening for type 2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(11):765–776. doi:10.7326/M14-2221.
   PubMed Web of Science ®Google Scholar
• Kaul K, Apostolopoulou M, Roden M. Insulin resistance in type 1 diabetes mellitus. Metabolism. 2015;64:1629–1639. doi:10.1016/j.metabol.2015.09.002.
   PubMed Web of Science ®Google Scholar
• Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2012;32(9):2052–2059. doi:10.1161/ATVBAHA.111.241919.
   PubMed Web of Science ®Google Scholar
• Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15(5):635–645. doi:10.1016/j.cmet.2012.04.001.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867. doi:10.1038/nature05376.
   PubMed Web of Science ®Google Scholar
• Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–184. doi:10.1172/JCI29881.
   PubMed Web of Science ®Google Scholar
• Bedinger DH, Adams SH. Metabolic, anabolic, and mitogenic insulin responses: a tissue-specific perspective for insulin receptor activators. Mol Cell Endocrinol. 2015;415:143–156. doi:10.1016/j.mce.2015.08.013.
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Karapanagiotou EM, Saif MW, et al. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev. 2009;35(2):148–159. doi:10.1016/j.ctrv.2008.09.006.
   PubMed Web of Science ®Google Scholar
• Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78(1):35–43. doi:10.1016/0092-8674(94)90570-3.
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6(11):1122–1128. doi:10.1038/ncb1183.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159–168. doi:10.1016/j.molcel.2006.03.029.
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293. doi:10.1016/j.cell.2012.03.017.
   PubMed Web of Science ®Google Scholar
• Gogas BD, McDaniel M, Samady H, et al. Novel drug-eluting stents for coronary revascularization. Trends Cardiovasc Med. 2014;24(7):305–313. doi:10.1016/j.tcm.2014.07.004.
   PubMed Web of Science ®Google Scholar
• Kedhi E, Gomes ME, Lagerqvist B, et al. Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: insights from a nationwide coronary intervention register. JACC Cardiovasc Interv. 2012;5(11):1141–1149. doi:10.1016/j.jcin.2012.06.020.
   PubMed Web of Science ®Google Scholar
• Rajagopalan N, Miller TD, Hodge DO, et al. Identifying high-risk asymptomatic diabetic patients who are candidates for screening stress single-photon emission computed tomography imaging. J Am Coll Cardiol. 2005;45(1):43–49. doi:10.1016/j.jacc.2004.06.078.
   PubMed Web of Science ®Google Scholar
• Scheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation. 1990;81(3):899–906. doi:10.1161/01.CIR.81.3.899.
   PubMed Web of Science ®Google Scholar
• Young LH, Wackers FJT, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA. 2009;301(15):1547–1555. doi:10.1001/jama.2009.476.
   PubMed Web of Science ®Google Scholar
• Lièvre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials. 2011;12:23. doi:10.1186/1745-6215-12-212.
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Lappé DL, Lima JAC, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes. JAMA. 2014;312(21):2234. doi:10.1001/jama.2014.15825.
   PubMed Web of Science ®Google Scholar
• Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboratio. Eur Heart J. 2013;34(39):3035–3087. doi:10.1093/eurheartj/eht108.
   PubMed Web of Science ®Google Scholar
• Brooks MM, Frye RL, Genuth S, et al. Hypotheses, design, and methods for the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am J Cardiol. 2006;97(12A):9G–19G. doi:10.1016/j.amjcard.2005.10.057.
   Google Scholar
• Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–2515. doi:10.1056/NEJMoa0805796.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–2384.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Blankenship JC, Alexander KP, et al. ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, a. J Am Coll Cardiol. 2014;64(18):1929–1949. doi:10.1016/j.jacc.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Ting HH, Chen AY, Roe MT, et al. Delay from symptom onset to hospital presentation for patients with non-ST-segment elevation myocardial infarction. Arch Intern Med. 2010;170(20):1834–1841. doi:10.1001/archinternmed.2010.328.
   PubMedGoogle Scholar
• Hasin T, Hochadel M, Gitt AK, et al. Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus. Am J Cardiol. 2009;103(6):772–778. doi:10.1016/j.amjcard.2008.11.034.
   PubMed Web of Science ®Google Scholar
• Norhammar A, Malmberg K, Rydén L, et al. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003;24(9):838–844. doi:10.1016/S0195-668X(02)00828-X.
   PubMed Web of Science ®Google Scholar
• Franklin K, Goldberg RJ, Spencer F, et al. Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events. Arch Intern Med. 2004;164(13):1457–1463. doi:10.1001/archinte.164.13.1457.
   PubMedGoogle Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC guideline for the management of patients with Non–ST-elevation acute coronary syndromes. J Am Coll Cardiol. 2014;64(24):e139–228. doi:10.1016/j.jacc.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet (London, England). 2000;355(9206):773–778. doi:10.1016/S0140-6736(05)72455-7.
   PubMed Web of Science ®Google Scholar
• Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111(23):3078–3086. doi:10.1161/CIRCULATIONAHA.104.517839.
   PubMed Web of Science ®Google Scholar
• van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–1367. doi:10.1056/NEJMoa011300.
   PubMed Web of Science ®Google Scholar
• Finfer S, Chittock DR, Su -SY-S, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–1297. doi:10.1056/NEJMoa0810625.
   PubMed Web of Science ®Google Scholar
• Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The bypass angioplasty revascularization investigation (BARI) investigators. N Engl J Med. 1996;335(4):217–225.
   PubMedGoogle Scholar
• Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–972. doi:10.1056/NEJMoa0804626.
   PubMed Web of Science ®Google Scholar
• Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35(40):2821–2830. doi:10.1093/eurheartj/ehu152.
   PubMed Web of Science ®Google Scholar
• Farkouh ME, Dangas G, Leon MB, et al. Design of the future REvascularization evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM) trial. Am Heart J. 2008;155(2):215–223. doi:10.1016/j.ahj.2007.10.012.
   PubMed Web of Science ®Google Scholar
• Bansilal S, Farkouh ME, Hueb W, et al. The future revascularization evaluation in patients with diabetes mellitus: optimal management of multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry. Am Heart J. 2012;164(4):591–599. doi:10.1016/j.ahj.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Farkouh ME, Sleeper LA, et al. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. J Am Coll Cardiol. 2014;64(12):1189–1197. doi:10.1016/j.jacc.2014.04.008.
   PubMed Web of Science ®Google Scholar
• Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002;40(5):946–953. doi:10.1016/S0735-1097(02)02065-X.
   PubMed Web of Science ®Google Scholar
• West NEJ, Ruygrok PN, Disco CMC, et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation. 2004;109(7):867–873. doi:10.1161/01.CIR.0000116750.63158.94.
   PubMed Web of Science ®Google Scholar
• Savage MP, Fischman DL, Schatz RA, et al. Coronary intervention in the diabetic patient: improved outcome following stent implantation compared with balloon angioplasty. Clin Cardiol. 2002;25(5):213–217. doi:10.1002/clc.4950250504.
   PubMed Web of Science ®Google Scholar
• Orr GA, Verdier-Pinard P, McDaid H, et al. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22(47):7280–7295. doi:10.1038/sj.onc.1206934.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31(5):335–340.
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Ellis SG, Dawkins KD, et al. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. J Am Coll Cardiol. 2008;51(7):708–715. doi:10.1016/j.jacc.2007.10.035.
   PubMed Web of Science ®Google Scholar
• Witzenbichler B, Wöhrle J, Guagliumi G, et al. Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circ Cardiovasc Interv. 2011;4(2):130–138. doi:10.1161/CIRCINTERVENTIONS.110.960245.
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (London, England). 2007;370(9591):937–948. doi:10.1016/S0140-6736(07)61444-5.
   PubMed Web of Science ®Google Scholar
• Garg P, Normand S-LT, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008;118(22):2277–2285. 7p following 2285. doi:10.1161/CIRCULATIONAHA.108.820159.
   PubMed Web of Science ®Google Scholar
• Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the Resolute zotarolimus-eluting coronary stent system in the treatment of de novo lesions in native coronary arteries: the RESOLUTE US clinical trial. J Am Coll Cardiol. 2011;57(17):1778–1783. doi:10.1016/j.jacc.2011.03.005.
   PubMed Web of Science ®Google Scholar
• Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (London, England). 2011;377(9773):1241–1247. doi:10.1016/S0140-6736(11)60395-4.
   PubMed Web of Science ®Google Scholar
• Hermiller JB, Fergus T, Pierson W, et al. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: a post hoc analysis of the SPIRIT III randomized trial. Am Heart J. 2009;158(6):1005–1010. doi:10.1016/j.ahj.2009.09.018.
   PubMed Web of Science ®Google Scholar
• Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299(16):1903–1913. doi:10.1001/jama.299.16.1903.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Pilgrim T, Heg D, et al. Comparative effectiveness and safety of new-generation versus early-generation drug-eluting stents according to complexity of coronary artery disease: a patient-level pooled analysis of 6,081 patients. JACC Cardiovasc Interv. 2015;8(13):1657–1666. doi:10.1016/j.jcin.2015.08.013.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8(6):e002230. doi:10.1161/CIRCINTERVENTIONS.114.002230.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Latib A, Panoulas VF, et al. Comparison of 2-year outcomes between zotarolimus-eluting and everolimus-eluting new-generation cobalt-chromium alloy stents in real-world diabetic patients. Catheter Cardiovasc Interv. 2015;86(1):E11–18. doi:10.1002/ccd.25797.
   Google Scholar
• Briguori C, Airoldi F, Visconti G, et al. Novel approaches for preventing or limiting events in diabetic patients (Naples-diabetes) trial: a randomized comparison of 3 drug-eluting stents in diabetic patients. Circ Cardiovasc Interv. 2011;4(2):121–129. doi:10.1161/CIRCINTERVENTIONS.110.959924.
   PubMed Web of Science ®Google Scholar
• Fröbert O, Lagerqvist B, Carlsson J, et al. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol. 2009;53(18):1660–1667. doi:10.1016/j.jacc.2009.01.054.
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Patel R, O’Shaughnessy C, et al. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv. 2009;2(10):967–976. doi:10.1016/j.jcin.2009.08.008.
   PubMed Web of Science ®Google Scholar
• Stone GW, Kedhi E, Kereiakes DJ, et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011;124(8):893–900. doi:10.1161/CIRCULATIONAHA.111.031070.
   PubMed Web of Science ®Google Scholar
• Kaul U, Bangalore S, Seth A, et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. N Engl J Med. 2015;373(18):1709–1719. doi:10.1056/NEJMoa1510188.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170. doi:10.1136/bmj.e5170.
   PubMedGoogle Scholar
• Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372(13):1213–1222. doi:10.1056/NEJMoa1412168.
   PubMed Web of Science ®Google Scholar
• Marui A, Kimura T, Nishiwaki N, et al. Five-year outcomes of percutaneous versus surgical coronary revascularization in patients with diabetes mellitus (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol. 2015;115(8):1063–1072. doi:10.1016/j.amjcard.2015.01.544.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44–122. doi:10.1016/j.jacc.2011.08.007.
   PubMed Web of Science ®Google Scholar
• Athappan G, Patvardhan E, Tuzcu ME, et al. Left main coronary artery stenosis: a meta-analysis of drug-eluting stents versus coronary artery bypass grafting. JACC Cardiovasc Interv. 2013;6(12):1219–1230. doi:10.1016/j.jcin.2013.07.008.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Caggegi A, Capranzano P, et al. Validating the EXCEL hypothesis: a propensity score matched 3-year comparison of percutaneous coronary intervention versus coronary artery bypass graft in left main patients with SYNTAX score ≤32. Catheter Cardiovasc Interv. 2011;77(7):936–943. doi:10.1002/ccd.22992.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364(17):1607–1616. doi:10.1056/NEJMoa1007994.
   PubMed Web of Science ®Google Scholar
• MacDonald MR, She L, Doenst T, et al. Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. Eur J Heart Fail. 2015;17(7):725–734. doi:10.1002/ejhf.288.
   PubMed Web of Science ®Google Scholar
• Ammirati E, Guida V, Latib A, et al. Determinants of outcome in patients with chronic ischemic left ventricular dysfunction undergone percutaneous coronary interventions. BMC Cardiovasc Disord. 2015;15:137. doi:10.1186/s12872-015-0126-x.
   PubMed Web of Science ®Google Scholar
• Park D-W, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA. 2014;312(19):2019–2027. doi:10.1001/jama.2014.15095.
   PubMed Web of Science ®Google Scholar
• Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J. 2007;28(14):1709–1716. doi:10.1093/eurheartj/ehm184.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Toklu B, Wetterslev J. Complete versus culprit-only revascularization for ST-segment-elevation myocardial infarction and multivessel disease: a meta-analysis and trial sequential analysis of randomized trials. Circ Cardiovasc Interv. 2015;8(4):e002142–e002142. doi:10.1161/CIRCINTERVENTIONS.114.002142.
   Web of Science ®Google Scholar
• Levine GN, O’Gara PT, Bates ER, et al. ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for t. J Am Coll Cardiol. 2015. doi:10.1016/j.jacc.2015.10.005.
   Web of Science ®Google Scholar
• Kleisli T, Cheng W, Jacobs MJ, et al. In the current era, complete revascularization improves survival after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2005;129(6):1283–1291. doi:10.1016/j.jtcvs.2004.12.034.
   PubMed Web of Science ®Google Scholar
• Nikolsky E, Gruberg L, C V P, et al. Percutaneous coronary interventions in diabetic patients: is complete revascularization important? J Invasive Cardiol. 2004;16(3):102–106.
   PubMedGoogle Scholar
• Jiménez-Navarro MF, López-Jiménez F, Barsness G, et al. Long-term prognosis of complete percutaneous coronary revascularisation in patients with diabetes with multivessel disease. Heart. 2015;101(15):1233–1239. doi:10.1136/heartjnl-2014-307143.
   PubMed Web of Science ®Google Scholar
• Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation. 2012;125(21):2613–2620. doi:10.1161/CIRCULATIONAHA.111.069237.
   PubMed Web of Science ®Google Scholar
• Van Nunen LX, Zimmermann FM, Tonino PAL, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet (London, England). 2015;386:1853–1860. doi:10.1016/S0140-6736(15)00057-4.
   PubMed Web of Science ®Google Scholar
• Généreux P, Palmerini T, Caixeta A, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol. 2012;59(24):2165–2174. doi:10.1016/j.jacc.2012.03.010.
   PubMed Web of Science ®Google Scholar
• Zimarino M, Ricci F, Romanello M, et al. Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. Catheter Cardiovasc Interv. 2015 Apr 2. doi:10.1002/ccd.25923. [Epub ahead of print].
   Web of Science ®Google Scholar
• Mosseri M, Nahir M, Rozenman Y, et al. Diffuse narrowing of coronary arteries in diabetic patients: the earliest phase of coronary artery disease. Cardiology. 1998;89(2):103–110. doi:10.1159/000006764.
   PubMed Web of Science ®Google Scholar
• Scanlon PJ, Faxon DP, Audet A-M, et al. ACC/AHA guidelines for coronary angiography11“ACC/AHA Guidelines for Coronary Angiography” was approved by the American College of Cardiology Board of Trustees in October 1998 and by the American Heart Association Science Advisory and Coordinating Committ. J Am Coll Cardiol. 1999;33(6):1756–1824. doi:10.1016/S0735-1097(99)00126-6.
   PubMed Web of Science ®Google Scholar
• Sarno G, Garg S, Onuma Y, et al. Impact of completeness of revascularization on the five-year outcome in percutaneous coronary intervention and coronary artery bypass graft patients (from the ARTS-II study). Am J Cardiol. 2010;106(10):1369–1375. doi:10.1016/j.amjcard.2010.06.069.
   PubMed Web of Science ®Google Scholar
• Yang HH, Chen Y, Gao CY. The influence of complete coronary revascularization on long-term outcomes in patients with multivessel coronary heart disease undergoing successful percutaneous coronary intervention. J Int Med Res. 2010;38(3):1106–1112. doi:10.1177/147323001003800339.
   PubMed Web of Science ®Google Scholar
• Head SJ, Mack MJ, Holmes DR, et al. Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. Eur J Cardiothorac Surg. 2012;41(3):535–541. doi:10.1093/ejcts/ezr105.
   PubMed Web of Science ®Google Scholar
• Kim MC, Jeong MH, Ahn Y, et al. What is optimal revascularization strategy in patients with multivessel coronary artery disease in non-ST-elevation myocardial infarction? Multivessel or culprit-only revascularization. Int J Cardiol. 2011;153(2):148–153. doi:10.1016/j.ijcard.2010.08.044.
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Park D-W, Lee J-Y, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation. 2011;123(21):2373–2381. doi:10.1161/CIRCULATIONAHA.110.005041.
   PubMed Web of Science ®Google Scholar
• Song YB, Lee S-Y, Hahn J-Y, et al. Complete versus incomplete revascularization for treatment of multivessel coronary artery disease in the drug-eluting stent era. Heart Vessels. 2012;27(5):433–442. doi:10.1007/s00380-011-0173-x.
   PubMed Web of Science ®Google Scholar
• Chung J-W, Park K-H, Lee M-H, et al. Benefit of complete revascularization in patients with multivessel coronary disease in the drug-eluting stent era. Circ J. 2012;76(7):1624–1630. doi:10.1253/circj.CJ-11-1285.
   PubMed Web of Science ®Google Scholar
• Gao Z, Xu B, Yang Y-J, et al. Long-term outcomes of complete versus incomplete revascularization after drug-eluting stent implantation in patients with multivessel coronary disease. Catheter Cardiovasc Interv. 2013;82(3):343–349. doi:10.1002/ccd.24799.
   PubMed Web of Science ®Google Scholar
• Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115–1123. doi:10.1056/NEJMoa1310345.
   PubMed Web of Science ®Google Scholar
• Reicher B, Poston RS, Mehra MR, et al. Simultaneous “hybrid” percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes. Am Heart J. 2008;155(4):661–667. doi:10.1016/j.ahj.2007.12.032.
   PubMed Web of Science ®Google Scholar
• Zimrin D, Reyes PA, Reicher B, et al. A hybrid alternative for high risk left main disease. Catheter Cardiovasc Interv. 2007;69(1):123–127. doi:10.1002/ccd.20914.
   PubMed Web of Science ®Google Scholar
• Cameron A, Davis KB, Green G, et al. Coronary bypass surgery with internal-thoracic-artery grafts—effects on survival over a 15-year period. N Engl J Med. 1996;334(4):216–220. doi:10.1056/NEJM199606133342404.
   PubMed Web of Science ®Google Scholar
• Hillis LD, Smith PK, Anderson JL, et al. ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic. J Am Coll Cardiol. 2011;58(24):e123–210. doi:10.1016/j.jacc.2011.08.009.
   PubMed Web of Science ®Google Scholar
• Harskamp RE, Walker PF, Alexander JH, et al. Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus. Am Heart J. 2014;168(4):471–478. doi:10.1016/j.ahj.2014.06.027.
   PubMed Web of Science ®Google Scholar
• Harskamp RE, Brennan JM, Xian Y, et al. Practice patterns and clinical outcomes after hybrid coronary revascularization in the United States: an analysis from the society of thoracic surgeons adult cardiac database. Circulation. 2014;130(11):872–879. doi:10.1161/CIRCULATIONAHA.114.009479.
   PubMed Web of Science ®Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.
   PubMed Web of Science ®Google Scholar
• Simpson SH, Gamble J-M, Mereu L, et al. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med. 2011;26(11):1336–1344. doi:10.1007/s11606-011-1757-y.
   PubMed Web of Science ®Google Scholar
• Fox CS, Golden SH, Anderson C, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2015;38(9):dci150012. doi:10.2337/dc14-1100.
   Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I. Circulation. 2008;118(16):1626–1636. doi:10.1161/CIRCULATIONAHA.108.791061.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi:10.1056/NEJMoa0706482.
   PubMed Web of Science ®Google Scholar
• Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038–1047. doi:10.1093/eurheartj/ehi754.
   PubMed Web of Science ®Google Scholar
• Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852–1856. doi:10.1016/j.jacc.2007.07.058.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi:10.1056/NEJMoa0904327.
   PubMed Web of Science ®Google Scholar
• James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2010;31(24):3006–3016. doi:10.1093/eurheartj/ehq113.
   PubMed Web of Science ®Google Scholar
• Tarantini G, Nai Fovino L, Tellaroli P, et al. Optimal duration of dual antiplatelet therapy after second-generation drug-eluting stent implantation in patients with diabetes: the SECURITY (Second-Generation Drug-Eluting Stent Implantation Followed By Six- Versus Twelve-Month Dual Antiplatelet Therapy. Int J Cardiol. 2016;207:168–176. doi:10.1016/j.ijcard.2016.01.068.
   PubMed Web of Science ®Google Scholar
• Rymer J, McCoy LA, Thomas L, et al. Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(10):1479–1484. doi:10.1016/j.amjcard.2014.08.010.
   PubMed Web of Science ®Google Scholar
• Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995;25(2):333–341. doi:10.1016/0735-1097(94)00397-9.
   PubMed Web of Science ®Google Scholar
• Chu D, Anastacio MM, Mulukutla SR, et al. Safety and efficacy of implementing a multidisciplinary heart team approach for revascularization in patients with complex coronary artery disease: an observational cohort pilot study. JAMA Surg. 2014;149(11):1109–1112. doi:10.1001/jamasurg.2014.2059.
   PubMed Web of Science ®Google Scholar
• Bonzel T, Schächinger V, Dörge H. Description of a Heart Team approach to coronary revascularization and its beneficial long-term effect on clinical events after PCI. Clin Res Cardiol. 2015 Oct 27. [Epub ahead of print].
   PubMedGoogle Scholar
• Price EL, Bereknyei S, Kuby A, et al. New elements for informed decision making: a qualitative study of older adults’ views. Patient Educ Couns. 2012;86(3):335–341. doi:10.1016/j.pec.2011.06.006.
   PubMed Web of Science ®Google Scholar
• Stacey D, Légaré F, Col NF, et al. Cochrane database of systematic reviews. Chichester (UK): John Wiley & Sons, Ltd; 2014 Jan 28;1:CD001431. doi:10.1002/14651858.CD001431.pub4.
   Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–2047. doi:10.1056/NEJMoa1503943.
   PubMed Web of Science ®Google Scholar
• Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):151013055541007. doi:10.1056/NEJMoa1509038.
   Web of Science ®Google Scholar
• International study of comparative health effectiveness with medical and invasive approaches (ISCHEMIA) - full text view - ClinicalTrials.gov [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT01471522.
   Google Scholar
• Campos CM, Van Klaveren D, Farooq V, et al. Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. Eur Heart J. 2015;36(20):1231–1241. doi:10.1093/eurheartj/ehu518.
   PubMed Web of Science ®Google Scholar
• Savonitto S, Cavallini C, Petronio AS, et al. Early aggressive versus initially conservative treatment in elderly patients with non-ST-segment elevation acute coronary syndrome: a randomized controlled trial. JACC Cardiovasc Interv. 2012;5(9):906–916. doi:10.1016/j.jcin.2012.06.008.
   PubMed Web of Science ®Google Scholar
• Barywani SB, Li S, M L, et al. Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality. Clin Interv Aging. 2015;10:1547–1553.
   PubMed Web of Science ®Google Scholar